Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders
- PMID: 20103661
- DOI: 10.1158/1078-0432.CCR-09-1766
Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders
Abstract
Purpose: Raf/mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK signaling pathway is constitutively activated in melanoma. AZD6244 blocks MEK1/2, inhibiting ERK phosphorylation. We focus on associated cutaneous toxicity and we attempt to understand the underlying pathophysiology and design treatment strategies.
Experimental design: Dermatologic conditions of 22 patients with unresectable melanoma stage III/IV in a phase II trial were evaluated. Thirteen patients received AZD6244 initially, and nine patients were treated with AZD6244 following tumor progression with temozolomide. Biopsies were compared with matched controls in normal skin. Immunohistochemistry was performed. Half-side treatment of acute skin toxicity compared therapeutic options.
Results: Nineteen of 22 (86%) AZD6244-treated patients presented with cutaneous eruptions. Seventeen patients (77%) developed acute papulopustular rash. Chronic skin changes included xerosis, paronychia, and fissured fingertips, resembling cutaneous toxicity of epidermal growth factor receptor inhibition. In addition, we observed reduced pigmentation of hair and skin. Histology of acute skin lesions revealed a significant increase of apoptotic keratinocytes (P = 0.0008), focal neutrophilic infiltrates, destruction of the adnexal structures by neutrophils, and reduced cytokeratins. A significant proliferation shift from basal to suprabasal keratinocytes was shown in acute and chronic lesions. The number and viability of melanocytes was not affected. Corticosteroids plus antibacterial topical therapy ameliorate acute skin toxicity.
Conclusions: AZD6244-associated skin reactions partly overlap with those observed upon epidermal growth factor receptor inhibition. Additionally, pigmentation of skin and hair is affected. The interruption of the MEK signaling pathway results in an acute keratinocyte stress response with disturbed epidermal homeostasis, inflammation, and tissue damage. Chronic adaptation controls inflammatory tissue damage but leads to cutaneous malfunctions that explain chronic skin toxicity.
Similar articles
-
Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.Clin Cancer Res. 2008 Oct 15;14(20):6396-404. doi: 10.1158/1078-0432.CCR-07-5113. Clin Cancer Res. 2008. PMID: 18927278
-
Mitogen-activated protein kinase kinase 1/extracellular signal-regulated kinase (MEK-1/ERK) inhibitors sensitize reduced glucocorticoid response mediated by TNFalpha in human epidermal keratinocytes (HaCaT).Biochem Biophys Res Commun. 2006 Dec 8;351(1):266-72. doi: 10.1016/j.bbrc.2006.10.032. Epub 2006 Oct 19. Biochem Biophys Res Commun. 2006. PMID: 17054908
-
AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma.Cancer. 2010 Mar 1;116(5):1315-25. doi: 10.1002/cncr.24863. Cancer. 2010. PMID: 20101735
-
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2371s-2375s. doi: 10.1158/1078-0432.CCR-05-2539. Clin Cancer Res. 2006. PMID: 16609061 Review.
-
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.Oncogene. 2007 May 14;26(22):3291-310. doi: 10.1038/sj.onc.1210422. Oncogene. 2007. PMID: 17496923 Review.
Cited by
-
A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia.Invest New Drugs. 2019 Dec;37(6):1247-1256. doi: 10.1007/s10637-019-00825-0. Epub 2019 Jun 26. Invest New Drugs. 2019. PMID: 31240513 Free PMC article. Clinical Trial.
-
Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature.Support Care Cancer. 2024 Aug 23;32(9):610. doi: 10.1007/s00520-024-08810-x. Support Care Cancer. 2024. PMID: 39174797
-
RASopathic skin eruptions during vemurafenib therapy.PLoS One. 2013;8(3):e58721. doi: 10.1371/journal.pone.0058721. Epub 2013 Mar 14. PLoS One. 2013. PMID: 23516541 Free PMC article. Clinical Trial.
-
High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.Blood. 2011 Feb 24;117(8):2433-40. doi: 10.1182/blood-2010-09-305128. Epub 2011 Jan 5. Blood. 2011. PMID: 21209378 Free PMC article.
-
A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis.ESMO Open. 2016 Jan 18;1(1):e000003. doi: 10.1136/esmoopen-2015-000003. eCollection 2016. ESMO Open. 2016. PMID: 27843579 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous